Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | terminated | Phase 2 | 24 | Wuhan UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT04110249 | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer | terminated | N/A | 14 | Roswell Park Cancer InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02890368 |
| Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides |
| terminated |
| Phase 1 |
| 56 |
| PfizerINDUSTRY |
| 1 |
| Apr 5, 2023 |
| clinicaltrials |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 30 | Celldex TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 15 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | terminated | Phase 1 / Phase 2 | 25 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | terminated | Early Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03906526 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | terminated | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 11 | Peking UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas(STARRS) | terminated | Phase 2 | 45 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 2 | 30 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | terminated | N/A | 2 | Aethlon Medical Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck(ERM-PT-HNSCC) | terminated | — | 12 | Leiden University Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03862066 | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | terminated | — | 2 | Medical University of South CarolinaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT03720158 | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients | terminated | N/A | 9 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Jul 25, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | terminated | Phase 2 | 3 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | terminated | Phase 2 | 137 | Boston Scientific CorporationINDUSTRY | 4 | Jun 22, 2022 | clinicaltrials |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02503111 | The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men(HPV-SAVE) | terminated | N/A | 71 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | terminated | Early Phase 1 | 1 | Presage BiosciencesINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma(ICING) | terminated | Phase 2 | 7 | UNICANCEROTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 12 | NYU Langone HealthOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | terminated | N/A | 19 | Emory UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT03875859 | Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) | terminated | Phase 2 | 4 | Kavita SarinOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer | terminated | N/A | 8 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03937791 | Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT00011492 | Patient Evaluation for Head and Neck Surgery Branch Studies | terminated | — | 62 | National Institute on Deafness and Other Communication Disorders (NIDCD)NIH | 1 | Nov 27, 2020 | clinicaltrials |
| NCT00503581 | Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia | terminated | Phase 2 | 9 | Gynecologic Oncology GroupNETWORK | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03276819 | A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC(UMBRELLA) | terminated | N/A | 53 | Centre Leon BerardOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2023source: clinicaltrials